RayKnowChina Research Map
Shortlist

Xi'anAir Force Medical University

Xijing Hospital

空军军医大学西京医院

Listed for 26 of the 53 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Xijing Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 53 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led1 open trial led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌22 papers led
  3. Hepatocellular carcinoma肝细胞癌58 papers led
  4. Stomach cancer胃癌62 papers led7 open trials led
  5. Hepatoblastoma肝母细胞瘤1 paper led
  6. Chordoma脊索瘤1 paper led
  7. Osteosarcoma骨肉瘤18 papers led
  8. Gastrointestinal stromal tumour胃肠道间质瘤4 papers led
  9. Neuroblastoma神经母细胞瘤2 papers led
  10. Ewing sarcoma尤文肉瘤2 papers led
  11. Multiple myeloma多发性骨髓瘤2 papers led
  12. B-cell acute lymphoblastic leukaemiaB 细胞急性淋巴细胞白血病1 paper led
  13. Thrombotic thrombocytopenic purpura血栓性血小板减少性紫癜1 paper led
  14. IgG4-related diseaseIgG4相关性疾病1 paper led
  15. Moyamoya disease烟雾病2 papers led
  16. Anti-NMDA receptor encephalitis抗 NMDA 受体脑炎3 papers led
  17. Takayasu arteritis大动脉炎3 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化1 paper led
  19. Duchenne muscular dystrophy杜氏肌营养不良0 papers led
  20. Behçet disease白塞病1 paper led
  21. IgA nephropathyIgA 肾病10 papers led
  22. Gaucher disease戈谢病0 papers led
  23. Niemann–Pick disease type C尼曼-匹克病 C 型1 paper led
  24. Primary biliary cholangitis原发性胆汁性胆管炎17 papers led6 open trials led
  25. Primary sclerosing cholangitis原发性硬化性胆管炎1 paper led
  26. Familial adenomatous polyposis家族性腺瘤性息肉病0 papers led

Not listed for: Retinoblastoma, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Fanconi anaemia, Neuromyelitis optica spectrum disorder, Myasthenia gravis, Wilson disease, Biliary atresia, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Alport syndrome, Osteogenesis imperfecta, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 2220212022: 0020222023: 1120232024: 0020242025: 222025

2 hospitals in Xi'an for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

Open trials with this hospital 3

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    GNT Induction Treatment in Locally Advanced NPC
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06026878

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  2. Recruiting
    Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III Trial
    Phase
    Phase 3
    Started
    2022-04
    Registry
    NCT05340491

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

  3. Recruiting
    PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma Patients
    Phase
    Phase 3
    Started
    2020-03
    Registry
    NCT03907826

    Age 18 years to 70 years (registered criteria)

    Led by Sun Yat-sen University Cancer Center; 10 listed hospitals as study sitesChengdu, Fuzhou, Guangzhou, Guiyang, Hangzhou, Nanchang, Nanning, Shanghai, Wuhan, Xi'an, Xiamen

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesRadiotherapy techniqueImaging & AIRecurrent / metastatic disease
Departments in papersRadiation oncology
Papers it led5
  1. A novel multimodal adaptive delineation model for primary tumors and lymph node metastases in multi-center nasopharyngeal carcinoma radiotherapy.2025Computer methods and programs in biomedicine
  2. A predictive model based on the dosimetric parameters of the parotid stem cell region to assess the recovery of radiation-induced xerostomia in long-term survivors of nasopharyngeal carcinoma after radical radiotherapy.2025Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
  3. Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage : A Multicenter Retrospective Study From Nonendemic Region of China.2023American journal of clinical oncology
  4. Prognostic analysis of 152 patients with distant metastasis after intensity-modulated radiotherapy for nasopharyngeal carcinoma.2021Annals of palliative medicine
  5. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma.2021Radiation oncology (London, England)Free full text
All its trials on ClinicalTrials.gov, any status6
  1. GNT Induction Treatment in Locally Advanced NPCRecruitingNCT06026878Lead (inferred)Phase 3Start 2023-09
  2. GP VS TP in the Treatment of Advanced Nasopharyngeal Carcinoma in Northwest ChinaCompletedNCT01596868Lead (inferred)Phase 2Start 2012-05
  3. Chemoradiotherapy Plus Anti-PD1 in Recurrent NPC: A Multicenter, Open-label, Randomised, Controlled, Phase III TrialRecruitingNCT05340491Study sitePhase 3Start 2022-04
  4. PD-1 Antibody Combined With Chemoradiotherapy in Recurrent Nasopharyngeal Carcinoma PatientsRecruitingNCT03907826Study sitePhase 3Start 2020-03
  5. PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal CarcinomaStatus unknownNCT03427827Study sitePhase 3Start 2018-07
  6. Sintilimab (PD-1 Antibody) and Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal CarcinomaStatus unknownNCT03700476Study sitePhase 3Start 2018-12
More papers found outside PubMed (not counted)14
  1. Development and Validation of a Hybrid Clinical-Delta Radiomics Model to Predict Distant Metastasis after Definitive Radio-Chemotherapy in Non-Endemic Nasopharyngeal Carcinoma2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. Iron Metabolism in Nasopharyngeal Carcinoma: Multi-Omics Exploration of Tumor Progression, Immune Microenvironment, and Radiotherapy Efficacy2025International Journal of Radiation Oncology*Biology*Physicsarticle
  3. Zero-Cost Customized Oral Stents Reduce Setup Errors in Nasopharyngeal Cancer Radiotherapy: Secondary Analysis of a Randomized Trial2025International Journal of Radiation Oncology*Biology*Physicsarticle
  4. Gross Tumor Volume Auto Delineation Based on a Novel Multimodal Adaptive Segmentation Model in Multicenter Nasopharyngeal Carcinoma Radiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Mechanistic of RBM3 Regulating Rad51 Alternative Splicing Mediated DNA Damage Repair Promoting Radioresistance of Nasopharyngeal Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  6. Prediction Study of Prognostic Nutrition Index on the Nausea and Vomiting of Patients with Cancer Undergoing Chemotherapy or Concurrent Chemoradiotherapy Based on Cisplatin2024International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Development and Validation of CT-Based Dose-Volume-Radiomics Nomogram for Radiation Induced Hypothyroidism in Nasopharyngeal Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  8. PD-1 blockade with sintilimab plus induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) versus IC-CCRT in locoregionally-advanced nasopharyngeal carcinoma (LANPC): A multicenter, phase 3, randomized controlled trial (CONTINUUM)2023Journal of Clinical Oncologyconference-abstract
  9. RBM3 Induced Immune Resistance through Modulating Tumor Microenvironment in Nasopharyngeal Carcinoma2022International Journal of Radiation Oncology*Biology*Physicsarticle
  10. The Effects of Multidimensional Individualized Clinical Management (MDICM) in Radiotherapy for Patients with Head and Neck Cancer: A Pilot Study2022International Journal of Radiation Oncology*Biology*Physicsarticle
  11. Detailed analysis of recovery process of cranial nerve palsy after IMRT-based comprehensive treatment in nasopharyngeal carcinoma2021Research Squarepreprint
  12. Induction Chemotherapy Followed by Concurrent Chemoradiotherapy vs. Concurrent Chemoradiotherapy in T4N0-1M0 Patients With Nasopharyngeal Carcinoma: A Multicenter Retrospective Study2021International Journal of Radiation Oncology*Biology*Physicsarticle
  13. Mechanistic Study of Irradiated Dying NPC Cells Promoting the Metastatic Ability of Surviving NPC Cells After Radiotherapy2021International Journal of Radiation Oncology*Biology*Physicsarticle
  14. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.2021Journal of Clinical Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 22 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
22
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 5520222023: 3320232024: 7720242025: 552025

5 hospitals in Xi'an for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapyNeoadjuvant & combined treatmentImaging & AI
Departments in papersRadiation oncologyGastroenterology / hepatologyPathology / laboratory medicine
Papers it led22
  1. Dual-Mode Radiosensitization of Esophageal Squamous Cell Carcinoma via SOCS6-Loaded Virus-Inspired Manganese-Bismuth Bimetallic Oxide Nanoparticles.2025Advanced healthcare materials
  2. Integration of machine learning in biomarker discovery for esophageal squamous cell carcinoma: Applications and future directions.2025Pathology, research and practice
  3. STC1 promotes esophageal squamous cell carcinoma progression and is associated with poor prognosis.2025Pathology, research and practice
  4. Impact of treatment time and waiting time on outcome for esophageal squamous cell carcinoma receiving definitive chemoradiotherapy.2025Radiation oncology (London, England)Free full text
  5. Comparison of radiation esophagitis associated with daytime versus evening radiotherapy in patients with esophageal carcinoma.2025Radiation oncology (London, England)Free full text
  6. RSK4 promotes the macrophage recruitment and M2 polarization in esophageal squamous cell carcinoma.2024Biochimica et biophysica acta. Molecular basis of disease
  7. Sirtuin1 (sirt1) regulates the glycolysis pathway and decreases cisplatin chemotherapeutic sensitivity to esophageal squamous cell carcinoma.2024Cancer biology & therapyFree full text
  8. Single-cell profiling of response to neoadjuvant chemo-immunotherapy in surgically resectable esophageal squamous cell carcinoma.2024Genome medicineFree full text
  9. A CT-based subregional radiomics nomogram for predicting local recurrence-free survival in esophageal squamous cell cancer patients treated by definitive chemoradiotherapy: a multicenter study.2024Journal of translational medicineFree full text
  10. Emerging role of cancer-associated fibroblasts in esophageal squamous cell carcinoma.2024Pathology, research and practice
  11. Long-term results of induction chemotherapy for non-operable esophageal squamous cell carcinoma followed by concurrent chemoradiotherapy: a single-centre experience.2024Radiology and oncologyFree full text
  12. The diagnostic performance of V' and U' variables as an objective index of pink-color sign for diagnosing esophageal cancerous lesions.2024Surgical endoscopy
  13. Mechanisms of radiotherapy resistance and radiosensitization strategies for esophageal squamous cell carcinoma.2023Molecular cancerFree full text
  14. Re-irradiation for local primary-recurrence esophageal squamous cell carcinoma treated with IMRT/VMAT.2023Radiation oncology (London, England)Free full text
  15. Pre-procedure oral administration of pronase improves efficacy of lugol chromoendoscopy in esophageal squamous cell carcinoma screening: a prospective, double-blinded, randomized, controlled trial.2023Surgical endoscopyRCT
  16. Clinical benefit of tunnel endoscopic submucosal dissection for esophageal squamous cancer: a multicenter, randomized controlled trial.2022Gastrointestinal endoscopyRCT
  17. Comparing N-acetylcysteine with sodium thiosulfate for relieving symptoms caused by Lugol's iodine chromoendoscopy: a randomized, double-blind trial.2022Gastrointestinal endoscopyRCT
  18. Cancer stem cells in esophageal squamous cell carcinoma.2022Pathology, research and practice
  19. Overexpression of OTX1 promotes tumorigenesis in patients with esophageal squamous cell carcinoma.2022Pathology, research and practice
  20. CT-based radiomics nomogram may predict local recurrence-free survival in esophageal cancer patients receiving definitive chemoradiation or radiotherapy: A multicenter study.2022Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and OncologyRCT
  21. Inhibition of SOCS6 confers radioresistance in esophageal squamous cell carcinoma.2021Biochemical and biophysical research communications
  22. Polygalacin D suppresses esophageal squamous cell carcinoma growth and metastasis through regulating miR-142-5p/Nrf2 axis.2021Free radical biology & medicine
All its trials on ClinicalTrials.gov, any status7
  1. High-concentration Small-volume Versus Low-concentration Large-volume Iodine Solution for Esophageal ChromoendoscopyCompletedNCT06063941Lead sponsorN/AStart 2023-10
  2. DCF Combined With Camrelizumab in the Treatment of Esophageal CancerStatus unknownNCT05050760Lead sponsorN/AStart 2021-09
  3. The Efficacy of N-acetylcysteine on Alleviating Symptom Caused by Lugol ChromoendoscopyCompletedNCT04764643Lead sponsorN/AStart 2020-02
  4. Efficacy and Safety of Endoscopic Submucosal Tunnel Dissection for Superficial Esophageal Squamous Cell CarcinomaCompletedNCT03404921Lead sponsorN/AStart 2018-01
  5. Real-world Experience of ICIs Plus Chemotherapy for Advanced ESCC.CompletedNCT05142709Study siteStart 2021-10
  6. Nimotuzumab in Combined With Paclitaxel and Cisplatin for Treatment of Metastatic Esophageal Squamous Cell CarcinomaStatus unknownNCT02611700Study sitePhase 3Start 2015-11
  7. Nimotuzumab in Combination With Chemoradiation for Local Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT01232374Study sitePhase 2Start 2010-09
More papers found outside PubMed (not counted)14
  1. A Longitudinal CT-Based Subregional Radiomics Nomogram for Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Treated with Definitive Chemoradiotherapy: A Multicenter Study2025International Journal of Radiation Oncology*Biology*Physicsarticle
  2. KDM6B Promotes the Development, Progression and Metastasis of Oesophageal Cancer through Demethylation of Histones in the LDHA Promoter Region2025Journal of Biological Regulators and Homeostatic Agents/Journal of Biological Regulators & Homeostatic Agentsarticle
  3. Comparison of Anlotinib and S-1 Combined with Radiotherapy in the Treatment of Elderly Patients with Inoperable Esophageal Squamous Cell Cancer: An Open-Label, Phase 2, Randomized Controlled Trial2024International Journal of Radiation Oncology*Biology*Physicsarticle
  4. Comparison of Radiation Esophagitis Associated with Morning vs. Evening Radiotherapy in Patients with Esophageal Squamous Cell Carcinoma2024International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Dolgoročni rezultati zdravljenja z indukcijsko kemoterapijo pri neoperabilnem ploščatoceličnem karcinomu požiralnika, ki ji je sledila sočasna kemoradioterapija2024DiRROS repository (University of Maribor)article
  6. Longitudinal CT Feature-Based Model for Predicting Local Recurrence Free Survival in Esophageal Cancer Patients Treated with Definitive Chemoradiotherapy: A Multicenter Study2024International Journal of Radiation Oncology*Biology*Physicsarticle
  7. Value of Peritumoral Radiomics in Predicting Local Recurrence-Free Survival in Esophageal Squamous Cell Carcinoma Receiving Definitive (Chemo)Radiotherapy2024International Journal of Radiation Oncology*Biology*Physicsarticle
  8. Clinical-Radiomics Nomogram for Risk Prediction of Esophageal Fistula in Patients with Esophageal Squamous Cell Carcinoma Treated by IMRT or VMAT2023International Journal of Radiation Oncology*Biology*Physicsarticle
  9. Effect of system analysis of reactive oxygen species on prognosis and treatment decisions for patients with esophageal squamous carcinoma.2023Journal of Clinical Oncologyconference-abstract
  10. Long-Term Results of Induction Chemotherapy for Esophageal Squamous Cell Carcinoma Receiving Concurrent Chemoradiotherapy2023International Journal of Radiation Oncology*Biology*Physicsarticle
  11. Re-Irradiation for Locally Primary Recurrence in Esophageal Squamous Cell Carcinoma Treated with IMRT/VMAT2023International Journal of Radiation Oncology*Biology*Physicsarticle
  12. Cortactin Expression Identifies Invasion Depth in Superficial Esophageal Squamous Cell Carcinoma2022SSRN Electronic Journalpreprint
  13. Correction: Cepharanthine hydrochloride reverses the mdr1 (P-glycoprotein)-mediated esophageal squamous cell carcinoma cell cisplatin resistance through JNK and p53 signals2021Oncotargeterratum
  14. Long-Term Clinical Outcome and Safety Analysis of Superficial Esophageal Cancer Patients Receiving Definite or Adjuvant/Salvage Radiotherapy2021International Journal of Radiation Oncology*Biology*Physicsarticle

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatocellular carcinoma

肝细胞癌

Led 58 of the 14,765 English-language PubMed papers on hepatocellular carcinoma with an author in mainland China, 2021–2025: 0.4%.

Papers led
58
2021–2025
Trials led
6
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 101020212022: 141420222023: 9920232024: 101020242025: 15152025

4 hospitals in Xi'an for hepatocellular carcinoma194 hospitals in China for hepatocellular carcinoma

No open trial on hepatocellular carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrence & prognosisImaging, AI & early detectionImmunotherapy & targeted drugs
Departments in papersSurgery (general/hepatobiliary/pancreatic)Gastroenterology / hepatologyMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led58
  1. A deep learning-based psi CT network effectively predicts early recurrence after hepatectomy in HCC patients.2025Abdominal radiology (New York)
  2. Surveillance and management of hepatocellular carcinoma after treatment of hepatitis C with direct-acting antiviral drugs.2025Annals of hepatology
  3. SLC25A35 enhances fatty acid oxidation and mitochondrial biogenesis to promote the carcinogenesis and progression of hepatocellular carcinoma by upregulating PGC-1α.2025Cell communication and signaling : CCSFree full text
  4. The Hippo-YAP signaling pathway promotes hepatocellular carcinoma progression by inducing FHL3 expression.2025Cell death & diseaseFree full text
  5. Cellular Membrane Protein GRINA is Highly Expressed and Associated with Survival Outcomes in Liver Cancer Patients.2025Current medical science
  6. The oncogenic role of BCL2L12 associated with immune status in the prognosis of human hepatocellular carcinoma.2025Die Naturwissenschaften
  7. Targeting METTL8 with Rabdosiin overcomes lenvatinib resistance in hepatocellular carcinoma.2025Experimental cell research
  8. Intratumoral bacterial load and tertiary lymphoid structure density in hepatocellular carcinoma: association and prognostic significance.2025Frontiers in immunologyFree full text
  9. ASPM mediates nuclear entrapment of FOXM1 via liquid-liquid phase separation to promote progression of hepatocarcinoma.2025Genome biologyFree full text
  10. DDX17-Mediated Upregulation of CXCL8 Promotes Hepatocellular Carcinoma Progression via Co-activating β-catenin/NF-κB Complex.2025International journal of biological sciencesFree full text
  11. CXCL12+ tumor-associated endothelial cells promote immune resistance in hepatocellular carcinoma.2025Journal of hepatology
  12. Prognostic model development using novel genetic signature associated with adenosine metabolism and immune status for patients with hepatocellular carcinoma.2025Journal of physiology and biochemistryFree full text
  13. Synergistic innate-adaptive immunity by NKG2D-specific CAR-macrophages drives durable remission in hepatocellular carcinoma.2025Molecular cancerFree full text
  14. The Knockdown of USP34 Inhibits the Progression of Hepatocellular Carcinoma by Accelerating c-Myc Degradation.2025The Turkish journal of gastroenterology : the official journal of Turkish Society of GastroenterologyFree full text
  15. Performance of Ultrasonography-Based Fractal Parameters in Distinguishing Hepatocellular Carcinoma From Intrahepatic Cholangiocarcinoma.2025Ultrasonic imaging
  16. Constructing a disulfidptosis-related prognostic signature of hepatocellular carcinoma based on single-cell sequencing and weighted co-expression network analysis.2024Apoptosis : an international journal on programmed cell death
  17. Identification of RCAN1's role in hepatocellular carcinoma using single-cell analysis.2024BMC cancerFree full text
  18. Development of a Novel CD8+ T Cell-Associated Signature for Prognostic Assessment in Hepatocellular Carcinoma.2024Cancer control : journal of the Moffitt Cancer CenterFree full text
  19. Targeting autophagy in HCC treatment: exploiting the CD147 internalization pathway.2024Cell communication and signaling : CCSFree full text
  20. Prediction Model and Nomogram of Early Recurrence of Hepatocellular Carcinoma after Ultrasound-guided Microwave Ablation.2024Current medical imaging
  21. Clinical Characteristics and Prognosis of Early-Onset Hepatocellular Carcinoma: A Retrospective Cohort Study Based on Population Data.2024Digestive diseases and sciences
  22. Long-term survival analysis of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma conforming to the Milan criteria: primary versus recurrent HCC.2024International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group
  23. The efficacy and safety of PD-1 inhibitor combined with TACE in the first-line treatment of unresectable hepatocellular carcinoma.2024Medical oncology (Northwood, London, England)
  24. Early versus Late Recurrence of Hepatocellular Carcinoma after Microwave Ablation: Patterns, Treatments, and Post-Recurrence Survival.2024Oncology
  25. CCDC58 is a potential biomarker for diagnosis, prognosis, immunity, and genomic heterogeneity in pan-cancer.2024Scientific reportsFree full text
  26. The deubiquitinating enzyme USP19 facilitates hepatocellular carcinoma progression through stabilizing YAP.2023Cancer letters
  27. Peritumor tertiary lymphoid structures are associated with infiltrating neutrophils and inferior prognosis in hepatocellular carcinoma.2023Cancer medicineFree full text
  28. Downregulated mitochondrial transcription factor A enhances mycoplasma infection to promote the metastasis of hepatocellular carcinoma.2023Cancer scienceFree full text
  29. Different 18F-FDG imaging: A rare case of liver multiple carcinomas.2023Clinics and research in hepatology and gastroenterology
  30. ASRGL1 downregulation suppresses hepatocellular carcinoma tumorigenesis in a CDK1-dependent manner.2023Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  31. EZH2-H3K27me3-mediated silencing of mir-139-5p inhibits cellular senescence in hepatocellular carcinoma by activating TOP2A.2023Journal of experimental & clinical cancer research : CRFree full text
  32. N6-methyladenosine RNA methylation in liver diseases: from mechanism to treatment.2023Journal of gastroenterology
  33. HMGB1-mediated elevation of KLF7 facilitates hepatocellular carcinoma progression and metastasis through upregulating TLR4 and PTK2.2023TheranosticsFree full text
  34. Targeting β-catenin and PD-L1 simultaneously by a racemic supramolecular peptide for the potent immunotherapy of hepatocellular carcinoma.2023TheranosticsFree full text
  35. Mitochondrial fission factor promotes cisplatin resistancein hepatocellular carcinoma.2022Acta biochimica et biophysica SinicaFree full text
  36. Galectin-9 expression predicts poor prognosis in hepatitis B virus-associated hepatocellular carcinoma.2022AgingFree full text
  37. Tubulin-binding peptide RR-171 derived from human umbilical cord serum displays antitumor activity against hepatocellular carcinoma via inducing apoptosis and activating the NF-kappa B pathway.2022Cell proliferationFree full text
  38. Low Expression of Phosphodiesterase 2 (PDE2A) Promotes the Progression by Regulating Mitochondrial Morphology and ATP Content and Predicts Poor Prognosis in Hepatocellular Carcinoma.2022CellsFree full text
  39. Identification of Potential Predictors of Prognosis and Sorafenib-Associated Survival Benefits in Patients with Hepatocellular Carcinoma after Transcatheter Arterial Chemoembolization.2022Current oncology (Toronto, Ont.)Free full text
  40. A Novel Oxidative Phosphorylation-Associated Gene Signature for Prognosis Prediction in Patients with Hepatocellular Carcinoma.2022Disease markersFree full text
  41. Prognostic Significance of CCDC137 Expression and Its Association with Immune Infiltration in Hepatocellular Carcinoma.2022Disease markersFree full text
  42. Tertiary lymphoid structures: Associated multiple immune cells and analysis their formation in hepatocellular carcinoma.2022FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  43. Overexpression of SLC25A51 promotes hepatocellular carcinoma progression by driving aerobic glycolysis through activation of SIRT5.2022Free radical biology & medicine
  44. Protective effect of tertiary lymphoid structures against hepatocellular carcinoma: New findings from a genetic perspective.2022Frontiers in immunologyFree full text
  45. Molecular pathogenesis: Connections between viral hepatitis-induced and non-alcoholic steatohepatitis-induced hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  46. M2-like tumor-associated macrophage-related biomarkers to construct a novel prognostic signature, reveal the immune landscape, and screen drugs in hepatocellular carcinoma.2022Frontiers in immunologyFree full text
  47. A novel immune checkpoint-related gene signature for hepatocellular carcinoma to predict clinical outcomes and therapeutic response.2022Mathematical biosciences and engineering : MBE
  48. m6A-Related Angiogenic Genes to Construct Prognostic Signature, Reveal Immune and Oxidative Stress Landscape, and Screen Drugs in Hepatocellular Carcinoma.2022Oxidative medicine and cellular longevityFree full text
  49. Potentiality of α-fetoprotein (AFP) and soluble intercellular adhesion molecule-1 (sICAM-1) in prognosis prediction and immunotherapy response for patients with hepatocellular carcinoma.2021BioengineeredFree full text
  50. Multiple-level copy number variations in cell-free DNA for prognostic prediction of HCC with radical treatments.2021Cancer scienceFree full text
  51. Down-regulation of SLC25A20 promotes hepatocellular carcinoma growth and metastasis through suppression of fatty-acid oxidation.2021Cell death & diseaseFree full text
  52. Cabozantinib-based combination therapy for the treatment of hepatocellular carcinoma.2021GutFree full text
  53. Increased expression of Cyclin F in liver cancer predicts poor prognosis: A study based on TCGA database.2021MedicineFree full text
  54. Total flavonoids of Radix Tetrastigma suppress inflammation-related hepatocellular carcinoma cell metastasis.2021Molecular genetics and genomics : MGGFree full text
  55. Potent antitumor activity of a glutamyltransferase-derived peptide via an activation of oncosis pathway.2021Scientific reportsFree full text
  56. Aberrantly high activation of a FoxM1-STMN1 axis contributes to progression and tumorigenesis in FoxM1-driven cancers.2021Signal transduction and targeted therapyFree full text
  57. Circulating tumour DNA methylation in hepatocellular carcinoma diagnosis using digital droplet PCR.2021The Journal of international medical researchFree full text
  58. Designer exosomes for targeted and efficient ferroptosis induction in cancer via chemo-photodynamic therapy.2021TheranosticsFree full text
Chinese-language papers (not in the count)2
  1. [Prediction of immune-related genes associated with prognosis in patients with hepatocellular carcinoma by bioinformatics methods].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  2. [T cell factor 3 (TCF3) is overexpressed in hepatocellular carcinoma and promotes their invasion and metastasis].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
All its trials on ClinicalTrials.gov, any status11
  1. A Study of CD147-targeted CAR-T by Hepatic Artery Infusions for Very Advanced Hepatocellular CarcinomaStatus unknownNCT03993743Lead sponsorPhase 1Start 2019-05
  2. Exploration of Noninvasive Differential Diagnosis of Benign and Malignant Liver TumorsStatus unknownNCT06524557Lead sponsorStart 2018-01
  3. Study of the Impact of Hypersplenism and Splenectomy on Hepatocarcinogenesis in Patients With Posthepatitic CirrhosisStatus unknownNCT01201655Lead sponsorStart 2010-01
  4. Drug-eluting Bead Transarterial Chemoembolisation (DEB-TACE) Versus (VS) Conventional Transarterial Chemoembolisation (cTACE) for Unresectable Hepatocellualr Carcinoma (HCC)Status unknownNCT03969576Lead (inferred)N/AStart 2020-09
  5. TACE With or Without Sorafenib in Intermediate Stage Hepatocellular CarcinomaStatus unknownNCT02529761Lead (inferred)N/AStart 2015-08
  6. Sorafenib Chemoembolization Evaluation Controlled TrialCompletedNCT01906216Lead (inferred)Phase 3Start 2013-09
  7. Liver Resection for Patients With Hepatocellular Carcinoma and Impaired Liver FunctionCompletedNCT06245785Study siteStart 2023-01
  8. Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal HypertensionCompletedNCT06245798Study siteStart 2023-01
  9. Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC)CompletedNCT02112656Study sitePhase 3Start 2014-06
  10. Safety and Efficacy of Arsenic Trioxide Contained in TACE in the Treatment of HCCStatus unknownNCT02018757Study sitePhase 2Start 2014-01
  11. Trans-catheter Chemo-embolization Combined With rAd-p53 Gene Injection in Treatment of Advanced Hepatocellular CarcinomaStatus unknownNCT02418988Study sitePhase 2Start 2014-07

Run the PubMed searchClinicalTrials.gov

Cancer

Stomach cancer

胃癌

Led 62 of the 9,782 English-language PubMed papers on stomach cancer with an author in mainland China, 2021–2025: 0.6%.

Papers led
62
2021–2025
Trials led
27
any status, ClinicalTrials.gov
Open trials led
7
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 9920212022: 9920222023: 161620232024: 7720242025: 21212025

5 hospitals in Xi'an for stomach cancer211 hospitals in China for stomach cancer

Open trials with this hospital 9

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Full-time RDI for ESD: Impact on Major Adverse Events and Procedure Time
    Phase
    N/A
    Started
    2026-03
    Registry
    NCT07401303

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  2. Recruiting
    Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract Cancers
    Phase
    Not given
    Started
    2026-08
    Registry
    NCT07600125

    Age 18 years to Not stated (registered criteria)

    Led by Xijing Hospital; 3 listed hospitals as study sitesDalian, Qingdao, Wuxi, Xi'an

  3. Recruiting
    A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07788196

    Age 18 years to Not stated (registered criteria)

    Led by Xijing HospitalXi'an

  4. Recruiting
    Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric Cancer
    Phase
    Not given
    Started
    2025-05
    Registry
    NCT06979895

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteXi'an

  5. Recruiting
    The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of Gastric
    Phase
    Not given
    Started
    2023-08
    Registry
    NCT05956847

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  6. Not yet recruiting
    Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label Study
    Phase
    Phase 2
    Started
    2026-07
    Registry
    NCT07685704

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  7. Not yet recruiting
    Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive Malignancies
    Phase
    N/A
    Started
    2025-06
    Registry
    NCT07014254

    Age 18 years to 80 years (registered criteria)

    Led by Xijing HospitalXi'an

  8. Recruiting
    Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07385703

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 64 listed hospitals as study sitesAnyang, Beijing, Changchun, Changsha, Changzhou, Chengde, Chengdu, Chongqing, Fuzhou, Guangzhou, Haikou, Hangzhou, Hefei, Jinan, Kunming, Lanzhou, Linyi, Luoyang, Nanchang, Nanchong, Nanjing, Qingdao, Shanghai, Shantou, Shenyang, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Urumqi, Wuhan, Xi'an, Xiamen, Xuzhou, Yangzhou, Zhengzhou

  9. Recruiting
    Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric Cancer
    Phase
    N/A
    Started
    2024-09
    Registry
    NCT06128252

    Age 18 years to 75 years (registered criteria)

    Led by Tangdu Hospital; 11 listed hospitals as study sitesChongqing, Nanjing, Shanghai, Shenyang, Urumqi, Wuhan, Xi'an

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesPeritoneal spread & advanced diseaseEarly detection & endoscopySurgery
Departments in papersGastroenterology / hepatologyPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)Radiology / nuclear medicine
Papers it led62
  1. Robotic Versus Laparoscopic Gastrectomy for Gastric Cancer: The Largest Systematic Reviews of 68,755 Patients and Meta-analysis.2025Annals of surgical oncology
  2. Comparison of short- and long-term outcomes among total laparoscopic, laparoscopic-assisted, and open total gastrectomies for advanced gastric cancer patients after neoadjuvant chemotherapy: a multicenter retrospective cohort study.2025BMC cancerFree full text
  3. Impact of anastomotic orientation (Upward vs. Downward) in Roux-en-Y reconstruction on duodenal stump leakage incidence after radical total gastrectomy: a retrospective comparative study.2025BMC cancerFree full text
  4. Short- and long-term outcomes of robotic- versus laparoscopic-assisted early-onset gastric cancer: a propensity score-matched retrospective cohort study.2025BMC cancerFree full text
  5. A prospective randomized study of the efficacy of continuous active warming in patients undergoing laparoscopic gastrectomy.2025BMC gastroenterologyRCTFree full text
  6. Extracellular vesicle-derived lncRNA-GC1 serves as a novel biomarker for predicting and monitoring the immunotherapeutic outcomes of patients with gastric cancer.2025BMC medicineFree full text
  7. Advancements in immunotherapy for gastric cancer: Unveiling the potential of immune checkpoint inhibitors and emerging strategies.2025Biochimica et biophysica acta. Reviews on cancer
  8. FXYD5 regulates gastric cancer cell metastasis and drug resistance by EMT modulation.2025Cancer gene therapy
  9. Evaluating the prognostic significance of tumor deposits in gastric cancer and strategies for their integration into the TNM staging system: a single-center retrospective study.2025Cellular oncology (Dordrecht, Netherlands)Free full text
  10. A Novel Prognostic Risk Model Based on Oxidative Stress to Predict Survival and Improve Treatment Strategies in Stomach Adenocarcinoma.2025Combinatorial chemistry & high throughput screening
  11. The proteomic and transcriptomic profiles of gastric mucosa from health volunteers.2025Computers in biology and medicine
  12. Diagnostic efficacy of an extracellular vesicle-derived lncRNA-based liquid biopsy signature for the early detection of early-onset gastric cancer.2025Gut
  13. Main results of a randomized controlled trial (RNPLS-01): efficacy and safety of ramucirumab combined with nab-paclitaxel, lobaplatin, and S-1 in neoadjuvant therapy for advanced gastric cancer.2025International journal of surgery (London, England)RCTFree full text
  14. Prediction of a Panel of Programmed Cell Death Protein-1 (PD-1) Inhibitor-Sensitive Biomarkers Using Multiphase Computed Tomography Imaging Textural Features: Retrospective Cohort Analysis.2025JMIR cancerFree full text
  15. UPP1/ARNT positive feedback loop drives gastric cancer progression through metabolism reprogramming.2025Medical oncology (Northwood, London, England)
  16. Interaction of PHGDH with IGF2BP1 facilitates m6A-dependent stabilization of TCF7L2 mRNA to confer multidrug resistance in gastric cancer.2025Oncogene
  17. The Fritillaria alkaloid peiminine acts as a chemosensitizer to potentiate oxaliplatin efficacy against gastric cancer.2025Pathology, research and practice
  18. Discovery of KMT5A repressed miR-99b cluster with potential to restore chemotherapy sensitivity in gastric cancer by regulating mitochondrial complex II and affecting OXPHOS.2025Pharmacological research
  19. The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.2025Surgical endoscopy
  20. Platinum drugs upregulate CXCR4 and PD-L1 expression via ROS-dependent pathways, with implications for novel combined treatment in gastric cancer.2025The journal of pathology. Clinical researchFree full text
  21. Comparison of the efficacy of TissuePatch™ versus no TissuePatch™ to seal pancreatic tissue surface for the prevention of pancreatic fistula after radical gastrectomy: study protocol for a prospective, single-center, randomized controlled t2025TrialsFree full text
  22. N6-methyladenosine reader hnRNPA2B1 recognizes and stabilizes NEAT1 to confer chemoresistance in gastric cancer.2024Cancer communications (London, England)Free full text
  23. YTHDC1 promotes the malignant progression of gastric cancer by promoting ROD1 translocation to the nucleus.2024Cell biology and toxicologyFree full text
  24. Biological functions of Circular RNA_LARP4/ Upstream frameshift 1 in development of gastric cancer.2024Cellular and molecular biology (Noisy-le-Grand, France)
  25. Emerging trends in early-onset gastric cancer.2024Chinese medical journalFree full text
  26. Analysis of Risk Factors for Gastric Cancer and Precancerous Lesions: A Case-Control Study.2024Journal of digestive diseasesFree full text
  27. The inflammation score predicts the prognosis of gastric cancer patients undergoing Da Vinci robot surgery.2024Journal of robotic surgery
  28. miR-107 reverses the multidrug resistance of gastric cancer by targeting the CGA/EGFR/GATA2 positive feedback circuit.2024The Journal of biological chemistryFree full text
  29. Log odds of positive lymph nodes as a novel prognostic predictor for gastric cancer: a systematic review and meta-analysis.2023BMC cancerFree full text
  30. Combining methylated SEPTIN9 and RNF180 plasma markers for diagnosis and early detection of gastric cancer.2023Cancer communications (London, England)Free full text
  31. Association of CDX2 and mucin expression with chemotherapeutic benefits in patients with stage II/III gastric cancer.2023Cancer medicineFree full text
  32. Cancer associated fibroblast derived SLIT2 drives gastric cancer cell metastasis by activating NEK9.2023Cell death & diseaseFree full text
  33. MG7-Ag, hTERT, and TFF2 identified high-risk intestinal metaplasia and constituted a prediction model for gastric cancer.2023Chinese medical journalFree full text
  34. Identification and validation of a novel prognostic circadian rhythm-related gene signature for stomach adenocarcinoma.2023Chronobiology international
  35. E3 ubiquitin ligase RNF180 prevents excessive PCDH10 methylation to suppress the proliferation and metastasis of gastric cancer cells by promoting ubiquitination of DNMT1.2023Clinical epigeneticsFree full text
  36. DNMT1 expression partially dictates 5-Azacytidine sensitivity and correlates with RAS/MEK/ERK activity in gastric cancer cells.2023EpigeneticsFree full text
  37. Development and validation of a ligand-receptor pairs signature to predict outcome and provide a therapeutic strategy in gastric cancer.2023Expert review of molecular diagnostics
  38. Sintilimab plus fluorouracil, leucovorin, oxaliplatin and docetaxel regimen as neoadjuvant therapy for resectable gastric cancer and biomarker exploration.2023Future oncology (London, England)
  39. A Liquid Biopsy Signature for the Early Detection of Gastric Cancer in Patients.2023Gastroenterology
  40. Relationship between gastric xanthoma, gastric precancerous lesions, and gastric cancer: A retrospective study.2023Journal of digestive diseases
  41. Endoscopic grading of gastric atrophy and histological gastritis staging on risk assessment for early gastric cancer: A case-control study.2023Journal of digestive diseases
  42. Identification and validation of a novel survival prediction model based on the T-cell phenotype in the tumor immune microenvironment and peripheral blood for gastric cancer prognosis.2023Journal of translational medicineFree full text
  43. Targeting the E3 ligase NEDD4 as a novel therapeutic strategy for IGF1 signal pathway-driven gastric cancer.2023OncogeneFree full text
  44. Comparing intracorporeal mechanical anastomosis vs. hand-sewn esophagojejunostomy after total laparoscopic gastrectomy for esophagogastric junction cancer: a single-center study.2023World journal of surgical oncologyFree full text
  45. Rho GTPase-activating protein 35 suppresses gastric cancer metastasis by regulating cytoskeleton reorganization and epithelial-to-mesenchymal transition.2022BioengineeredFree full text
  46. Sec62 promotes gastric cancer metastasis through mediating UPR-induced autophagy activation.2022Cellular and molecular life sciences : CMLSFree full text
  47. Bile reflux and bile acids in the progression of gastric intestinal metaplasia.2022Chinese medical journalFree full text
  48. Circulating exosomal gastric cancer-associated long noncoding RNA1 as a noninvasive biomarker for predicting chemotherapy response and prognosis of advanced gastric cancer: A multi-cohort, multi-phase study.2022EBioMedicineFree full text
  49. Case report: Long response to PD-1 blockade after failure of trastuzumab plus chemotherapy in advanced Epstein-Barr virus-associated gastric cancer.2022Frontiers in immunologyFree full text
  50. MiR-585-5p impedes gastric cancer proliferation and metastasis by orchestrating the interactions among CREB1, MAPK1 and MITF.2022Frontiers in immunologyFree full text
  51. E2F1-mediated up-regulation of TOP2A promotes viability, migration, and invasion, and inhibits apoptosis of gastric cancer cells.2022Journal of biosciences
  52. Effects of mRNA expression of five Notch ligands on prognosis of gastric carcinoma.2022Scientific reportsFree full text
  53. A CGA/EGFR/GATA2 positive feedback circuit confers chemoresistance in gastric cancer.2022The Journal of clinical investigationFree full text
  54. Total Laparoscopic Uncut Roux-en-Y for Radical Distal Gastrectomy: An Interim Analysis of a Randomized, Controlled, Clinical Trial.2021Annals of surgical oncologyRCT
  55. Association of systemic inflammation and body mass index with survival in patients with resectable gastric or gastroesophageal junction adenocarcinomas.2021Cancer biology & medicineFree full text
  56. Is intestinal metaplasia the point of no return in the progression of gastric carcinogenesis?2021Chinese medical journalFree full text
  57. Circular RNA PTK2 Accelerates Cell Proliferation and Inhibits Cell Apoptosis in Gastric Carcinoma via miR-139-3p.2021Digestive diseases and sciences
  58. HDAC6/HNF4α loop mediated by miR-1 promotes bile acids-induced gastric intestinal metaplasia.2021Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer AssociationFree full text
  59. Bile reflux is an independent risk factor for precancerous gastric lesions and gastric cancer: An observational cross-sectional study.2021Journal of digestive diseasesFree full text
  60. Impact of Laparoscopic Converted to Open Gastrectomy on Short- and Long-Term Outcomes of Patients with Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.2021Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  61. Resveratrol inhibits bile acid-induced gastric intestinal metaplasia via the PI3K/AKT/p-FoxO4 signalling pathway.2021Phytotherapy research : PTRFree full text
  62. NEK9, a novel effector of IL-6/STAT3, regulates metastasis of gastric cancer by targeting ARHGEF2 phosphorylation.2021TheranosticsFree full text
Chinese-language papers (not in the count)8
  1. [Gastrointestinal hamartomatous inverted hyperplastic polyps: a clinicopathological analysis of ten cases].2025Zhonghua bing li xue za zhi = Chinese journal of pathology
  2. [Visualizing the evidence of robotic gastrointestinal surgery based on guideline recommendations: an evidence mapping study of gastric and colorectal cancer].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  3. [Comparison of short-term safety and efficacy among total laparoscopic, laparoscopy-assisted, and open radical total gastrectomy after neoadjuvant therapy: a multicenter retrospective study].2025Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  4. [The correlation between No. 6 and No. 14v lymph node metastasis and the value of dissecting these lymph nodes in radical gastrectomy].2023Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  5. [N6-methyladenosine (m6A) binding protein hnRNPA2B1 is highly expressed in a variety of tumors and regulates tumor immune microenvironment].2022Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
  6. [Patient experience in the implementation of enhanced recovery after surgery strategy after radical gastric cancer surgery].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  7. [Management of anastomotic leakage after laparoscopic surgery for adenocarcinoma of esophagogastric junction].2022Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
  8. [Functional evaluation after function-preserving gastrectomy].2021Zhonghua wei chang wai ke za zhi = Chinese journal of gastrointestinal surgery
All its trials on ClinicalTrials.gov, any status37
  1. Evaluation of Fecal Multi-target Biomarkers in the Screening of Digestive Tract CancersRecruitingNCT07600125Lead sponsorStart 2026-08
  2. Full-time RDI for ESD: Impact on Major Adverse Events and Procedure TimeRecruitingNCT07401303Lead sponsorN/AStart 2026-03
  3. A Clinical Study Comparing Anti-HER2 Therapy Combined With Chemotherapy to Chemotherapy Alone as Adjuvant Therapy Following Surgery for Stage IB-II Gastric Cancer With High HER2 Expression.RecruitingNCT07788196Lead sponsorPhase 2Start 2026-07
  4. Investigating Multigene Methylation Dynamics in Treatment Response Surveillance for Gastric CancerRecruitingNCT06979895Lead sponsorStart 2025-05
  5. Therapeutic Study of 177Lu-CTR-FAPI in Advanced Metastatic Digestive MalignanciesNot yet recruitingNCT07014254Lead sponsorN/AStart 2025-06
  6. The Role of Extracellular DNA (ecDNA) in the Occurrence and Development of GastricRecruitingNCT05956847Lead sponsorStart 2023-08
  7. Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric JunctionActive, not recruitingNCT06576921Lead sponsorPhase 2Start 2024-11
  8. ERAS in Totally Laparoscopic Total Gastrectomy for Gastric CancerStatus unknownNCT06489288Lead sponsorN/AStart 2024-05
  9. Application of Serum Bile Acid Profile in the Diagnosis of Gastric CancerCompletedNCT06031779Lead sponsorStart 2023-05
  10. An Exploratory Study of Immunotherapy Combined With Anlotinib and Chemotherapy in Perioperative Treatment of LAGCStatus unknownNCT05800080Lead sponsorN/AStart 2023-04
  11. Effects of High-dose Dual Therapy and Bismuth Quadruple Therapy for Helicobacter Pylori Eradication on Intestinal MicroecologyCompletedNCT05742568Lead sponsorPhase 4Start 2022-12
  12. A Study on the Relationship Between Gastric Xanthoma and Gastric Cancer and Precancerous LesionsCompletedNCT06282484Lead sponsorStart 2022-09
  13. Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple TherapyCompletedNCT04697186Lead sponsorPhase 4Start 2021-01
  14. Early Diagnosis of Gastric Cancer CachexiaStatus unknownNCT06277986Lead sponsorStart 2021-06
  15. A Real World Study of Bismuth Colloidal Pectin Granules Quadruple Therapy for H. Pylori EradicationCompletedNCT04660123Lead sponsorPhase 4Start 2020-12
  16. Helicobacter Pylori Eradication With Different Bismuth Quadruple TherapiesCompletedNCT04209933Lead sponsorPhase 4Start 2020-05
  17. Associations Among Serum and Gastric Juice Bile Acid Profile, Bile Acid-microbiota Cross-talk in Stomach and the Development of Gastric CancerCompletedNCT04660058Lead sponsorStart 2020-12
  18. Helicobacter Rescue Therapy With High-dose Esomeprazole and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple TherapyCompletedNCT04678492Lead sponsorPhase 4Start 2020-12
  19. Study on the Effect of Bile Reflux on Gastric Cancer and Its Precancerous Lesions: a Cross-sectional Study.CompletedNCT03976739Lead sponsorStart 2019-06
  20. Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple TherapyCompletedNCT03609892Lead sponsorPhase 4Start 2018-08
  21. The Efficacy of Esomeprazole Premedication on Intraoperative Bleeding During Gastric ESDCompletedNCT02730533Lead sponsorN/AStart 2016-03
  22. The Feasible Research of Infrared Endoscope to Diagnose Early Gastric CancerStatus unknownNCT02710838Lead sponsorN/AStart 2014-01
  23. Comparison of O-type Hybrid Knife and IT Knife in ESDCompletedNCT01760070Lead sponsorN/AStart 2012-12
  24. Zanidatamab Combined With Chemotherapy as Neoadjuvant/Conversion Therapy for HER2-Positive (IHC 3+ or IHC 2+) Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a Phase II Open-Label StudyNot yet recruitingNCT07685704Lead (inferred)Phase 2Start 2026-07
  25. Ramucirumab Combined With Nab-paclitaxel, Lobaplatin, and S-1 in Neoadjuvant Transformation Therapy for Advanced Gastric CancerStatus unknownNCT06169410Lead (inferred)Phase 4Start 2023-12
  26. The Influence of Splenic Artery Characteristics in Gastric Cancer SurgeryActive, not recruitingNCT06680362Lead (inferred)Start 2022-05
  27. Nab-paclitaxel Combined With Oxaliplatin and S-1 for Perioperative Treatment of Advanced Gastric CancerStatus unknownNCT05052931Lead (inferred)Phase 2Start 2021-10
  28. Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.RecruitingNCT07385703Study sitePhase 3Start 2026-04
  29. Clinical Study of Taurine Combined With Neoadjuvant Chemo-Immunotherapy for Treatment of Locally Advanced Gastric CancerRecruitingNCT06128252Study siteN/AStart 2024-09
  30. Prospective Screening and Differentiating Common Cancers Using Peripheral Blood Cell-Free DNA SequencingStatus unknownNCT06036563Study siteStart 2023-09
  31. Gastric Cancer Early Detection by Multi-dimensional Analysis of cfDNAStatus unknownNCT05668910Study siteStart 2022-09
  32. PD1 Combined With Chemotherapy for Adjuvant Treatment of Gastric CancerActive, not recruitingNCT05180734Study sitePhase 3Start 2022-02
  33. Robotic Versus Laparoscopic Distal Gastrectomy With D2 Lymphadenectomy for Locally Advanced Gastric CancerStatus unknownNCT03273920Study siteN/AStart 2017-09
  34. Preoperative Stomach Cancer Induction Chemotherapy and Radiation TherapyStatus unknownNCT03223740Study sitePhase 3Start 2016-09
  35. Roux-en-Y vs. Roux-en-Y+ Pouch for D2 Total GastrectomyStatus unknownNCT02110628Study sitePhase 3Start 2014-08
  36. A Study of Pertuzumab in Combination With Trastuzumab and Chemotherapy in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Metastatic Gastroesophageal Junction or Gastric CancerCompletedNCT01774786Study sitePhase 3Start 2013-06
  37. A Non-Interventional Study of Treatment Pattern and Clinical Outcomes in Chinese Participants With Gastric CancerCompletedNCT01839500Study siteStart 2013-04

Run the PubMed searchClinicalTrials.gov

Cancer

Hepatoblastoma

肝母细胞瘤

Led 1 of the 154 English-language PubMed papers on hepatoblastoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

5 hospitals in Xi'an for hepatoblastoma86 hospitals in China for hepatoblastoma

No open trial on hepatoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineSurgery (general/hepatobiliary/pancreatic)
Papers it led1
  1. Mitochondrial fragmentation is crucial for c-Myc-driven hepatoblastoma-like liver tumors.2022Molecular therapy : the journal of the American Society of Gene Therapy
Chinese-language papers (not in the count)1
  1. [Hepatoblastoma in elderly female: report of a case].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Cancer

Chordoma

脊索瘤

Led 1 of the 105 English-language PubMed papers on chordoma with an author in mainland China, 2021–2025: 0.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

5 hospitals in Xi'an for chordoma84 hospitals in China for chordoma

No open trial on chordoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 18 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.8%.

Papers led
18
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 3320222023: 6620232024: 3320242025: 112025

11 hospitals in Xi'an for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicine
Papers it led18
  1. Curculigoside exhibits multiple therapeutic efficacy to induce apoptosis and ferroptosis in osteosarcoma via modulation of ROS and tumor microenvironment.2025Tissue & cell
  2. Unraveling T cell exhaustion in the immune microenvironment of osteosarcoma via single-cell RNA transcriptome.2024Cancer immunology, immunotherapy : CII
  3. The Potential Therapeutic Targets of Anlotinib in Osteosarcoma: Characterization Based on Patient-Derived Xenografts and Next-Generation Sequencing.2024Cancer medicine
  4. A deep learning model for accurately predicting cancer-specific survival in patients with primary bone sarcoma of the extremity: a population-based study.2024Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  5. Characterization of myeloid signature genes for predicting prognosis and immune landscape in Ewing sarcoma.2023Cancer science
  6. Deciphering the heterogeneity and immunosuppressive function of regulatory T cells in osteosarcoma using single-cell RNA transcriptome.2023Computers in biology and medicine
  7. Anoikis patterns exhibit distinct prognostic and immune landscapes in Osteosarcoma.2023International immunopharmacology
  8. Predicting chemosensitivity based on mini patient-derived xenografts in osteosarcoma patients: A retrospective study.2023Journal of cancer research and therapeutics
  9. A classification system of joint-salvage tumor resection in osteosarcoma of the knee: A retrospective cohort study.2023The Knee
  10. Does joint-sparing tumor resection jeopardize oncologic and functional outcomes in non-metastatic high-grade osteosarcoma around the knee?2023World journal of surgical oncology
  11. Is the Capanna Technique a Reliable Method for Revision Surgery after Failure of Previous Limb-Salvage Surgery?2022Annals of surgical oncology
  12. Intercalary tibial reconstruction with frozen tumor-bearing autograft in combination with ipsilateral fibula in limb-salvage surgery.2022Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  13. Lateral Malleolus Reconstruction After Tumor Resection in Children: A Case Report and Literature Review.2022Orthopaedic surgery
  14. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.2021Annals of palliative medicine
  15. Use of Vascularized Fibular Epiphyseal Transfer with Massive Bone Allograft for Proximal Humeral Reconstruction in Children with Bone Sarcoma.2021Annals of surgical oncology
  16. Prognostic value of tumoral and peritumoral magnetic resonance parameters in osteosarcoma patients for monitoring chemotherapy response.2021European radiology
  17. The Synergistic Reducing Drug Resistance Effect of Cisplatin and Ursolic Acid on Osteosarcoma through a Multistep Mechanism Involving Ferritinophagy.2021Oxidative medicine and cellular longevity
  18. Cryoablation-aided joint retention surgery for epiphysis involvement in osteosarcoma compared with endoprosthetic replacement.2021The bone & joint journal
Earlier papers (2016–2020)8
  1. Primary Osteosarcoma of the Liver: Case Report and Literature Review.2020Pathology oncology research : POR
  2. Factors Influencing Osseous Union Following Surgical Treatment of Bone Tumors with Use of the Capanna Technique.2019The Journal of bone and joint surgery. American volume
  3. HSP90AA1-mediated autophagy promotes drug resistance in osteosarcoma.2018Journal of experimental & clinical cancer research : CR
  4. Honokiol induces autophagy and apoptosis of osteosarcoma through PI3K/Akt/mTOR signaling pathway.2018Molecular medicine reports
  5. What are the Oncologic and Functional Outcomes After Joint Salvage Resections for Juxtaarticular Osteosarcoma About the Knee?2017Clinical orthopaedics and related research
  6. [Detection and clinical significance of circulating tumor cells in osteosarcoma using immunofluorescence combined with in situ hybridization].2017Zhonghua zhong liu za zhi [Chinese journal of oncology]
  7. Extracorporeally frozen tumour-bearing bone combined with free vascularised fibula for the intercalary reconstruction of femoral defect after resection of bony sarcoma.2016Journal of plastic, reconstructive & aesthetic surgery : JPRAS
  8. Preliminary Application of Precision Genomic Medicine Detecting Gene Variation in Patients with Multifocal Osteosarcoma.2016Orthopaedic surgery
All its trials on ClinicalTrials.gov, any status1
  1. A Study of Endostar Combined With Chemotherapy for Treatment of OsteosarcomaStatus unknownNCT01002092Study sitePhase 2Start 2009-02

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 4 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.8%.

Papers led
4
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 332025

3 hospitals in Xi'an for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology
Papers it led4
  1. Regulatory roles of non-coding RNAs in programmed cell death pathways and drug resistance in gastrointestinal stromal tumors.2025Clinical and experimental medicine
  2. An interpretable machine learning framework for automated mitosis detection in gastrointestinal stromal tumors.2025Pathology, research and practice
  3. The progression rate and risk factor analysis of small gastric subepithelial tumors: a systematic review and meta-analysis.2025Surgical endoscopy
  4. Development and validation of a prognostic nomogram for gastrointestinal stromal tumors in the postimatinib era: A study based on the SEER database and a Chinese cohort.2023Cancer medicine
Earlier papers (2016–2020)14
  1. Current characteristics on small intestinal stromal tumor-a case control study.2020Annals of palliative medicine
  2. A multivariate prediction model for high malignancy potential gastric GI stromal tumors before endoscopic resection.2020Gastrointestinal endoscopy
  3. Genetic alterations in cell cycle regulation-associated genes may promote primary progression of gastrointestinal stromal tumors.2020Laboratory investigation; a journal of technical methods and pathology
  4. Clinicopathological Features and Prognosis of Gastrointestinal Stromal Tumor Located in the Jejunum and Ileum.2019Digestive surgery
  5. Clinicopathological features, surgical strategy and prognosis of duodenal gastrointestinal stromal tumors: a series of 300 patients.2018BMC cancer
  6. Meta-analysis comparing laparoscopic versus open resection for gastric gastrointestinal stromal tumors larger than 5 cm.2017BMC cancer
  7. Pancreatic Gastrointestinal Stromal Tumor: Clinicopathologic Features and Prognosis.2017Journal of clinical gastroenterology
  8. Clinicopathological features and prognosis of mesenteric gastrointestinal stromal tumor: evaluation of a pooled case series.2017Oncotarget
  9. Clinicopathological feature and prognosis of primary hepatic gastrointestinal stromal tumor.2016Cancer medicine
  10. Clinicopathological features and prognosis of coexistence of gastric gastrointestinal stromal tumor and gastric cancer.2016Medicine
  11. Combination of PLR, MLR, MWR, and Tumor Size Could Significantly Increase the Prognostic Value for Gastrointestinal Stromal Tumors.2016Medicine
  12. Clinicopathologic Features and Clinical Outcomes of Esophageal Gastrointestinal Stromal Tumor: Evaluation of a Pooled Case Series.2016Medicine
  13. Clinicopathological features and prognosis of colonic gastrointestinal stromal tumors: evaluation of a pooled case series.2016Oncotarget
  14. Clinicopathological features and prognosis of omental gastrointestinal stromal tumor: evaluation of a pooled case series.2016Scientific reports
All its trials on ClinicalTrials.gov, any status1
  1. Exploring the Molecular Mechanism Based on KIT MutationStatus unknownNCT05895942Lead sponsorStart 2021-09

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 1120242025: 002025

12 hospitals in Xi'an for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Ewing sarcoma

尤文肉瘤

Led 2 of the 163 English-language PubMed papers on Ewing sarcoma with an author in mainland China, 2021–2025: 1.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 0020242025: 002025

4 hospitals in Xi'an for Ewing sarcoma134 hospitals in China for Ewing sarcoma

No open trial on Ewing sarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Multiple myeloma

多发性骨髓瘤

Led 2 of the 1,676 English-language PubMed papers on multiple myeloma with an author in mainland China, 2021–2025: 0.1%.

Papers led
2
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 112025

4 hospitals in Xi'an for multiple myeloma175 hospitals in China for multiple myeloma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 8 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
    Phase
    Not given
    Started
    2026-06
    Registry
    NCT07663253

    Age 18 years to Not stated (registered criteria)

    Led by Zhongshan Hospital, Fudan University; 9 listed hospitals as study sitesBeijing, Chengdu, Guangzhou, Kunming, Nanning, Nantong, Shanghai, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
ThemesDiagnosis, MRD & riskKidney & bone complications
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Blood disorders

B-cell acute lymphoblastic leukaemia

B 细胞急性淋巴细胞白血病

Led 1 of the 225 English-language PubMed papers on B-cell acute lymphoblastic leukaemia with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

4 hospitals in Xi'an for B-cell acute lymphoblastic leukaemia88 hospitals in China for B-cell acute lymphoblastic leukaemia

No open trial on B-cell acute lymphoblastic leukaemia lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesStem cell transplantPhiladelphia chromosome & genetics

Run the PubMed searchClinicalTrials.gov

Blood disorders

Thrombotic thrombocytopenic purpura

血栓性血小板减少性紫癜

Led 1 of the 64 English-language PubMed papers on thrombotic thrombocytopenic purpura with an author in mainland China, 2021–2025: 1.6%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Xi'an for thrombotic thrombocytopenic purpura59 hospitals in China for thrombotic thrombocytopenic purpura

No open trial on thrombotic thrombocytopenic purpura lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

IgG4-related disease

IgG4相关性疾病

Led 1 of the 246 English-language PubMed papers on IgG4-related disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

1 hospital in Xi'an for IgG4-related disease46 hospitals in China for IgG4-related disease

No open trial on IgG4-related disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesPancreas & bile ducts
Departments in papersGastroenterology / hepatology
Papers it led1
  1. Recent advances in IgG4-related autoimmune pancreatitis.2024Pathology, research and practice
Chinese-language papers (not in the count)2
  1. [Analysis of clinical characteristics and current diagnosis and treatment status of IgG4-related diseases in the real world].2025Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatologyFree full text
  2. [IgG4-related diseases of the gastrointestinal tract].2025Zhonghua nei ke za zhi

Run the PubMed searchClinicalTrials.gov

Other diseases

Moyamoya disease

烟雾病

Led 2 of the 356 English-language PubMed papers on moyamoya disease with an author in mainland China, 2021–2025: 0.6%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 1120242025: 002025

1 hospital in Xi'an for moyamoya disease47 hospitals in China for moyamoya disease

No open trial on moyamoya disease lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesImaging & blood flowRevascularisation surgery
Departments in papersNeurosurgery

Run the PubMed searchClinicalTrials.gov

Other diseases

Anti-NMDA receptor encephalitis

抗 NMDA 受体脑炎

Led 3 of the 264 English-language PubMed papers on anti-NMDA receptor encephalitis with an author in mainland China, 2021–2025: 1.1%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 2220222023: 0020232024: 1120242025: 002025

3 hospitals in Xi'an for anti-NMDA receptor encephalitis124 hospitals in China for anti-NMDA receptor encephalitis

No open trial on anti-NMDA receptor encephalitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led 3 of the 187 English-language PubMed papers on Takayasu arteritis with an author in mainland China, 2021–2025: 1.6%.

Papers led
3
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 0020232024: 0020242025: 112025

3 hospitals in Xi'an for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiology / nuclear medicineRheumatology & immunology
Papers it led3
  1. Brain computed tomography perfusion alterations in patients with Takayasu arteritis with steno-occlusive carotid arteries: a retrospective study.2025Clinical rheumatology
  2. The establishment and validation of reference intervals for plasma Pentraxin-3 in healthy volunteers and patients with Takayasu's arteritis.2022Clinica chimica acta; international journal of clinical chemistry
  3. Acute myocardial infarction with left main coronary artery ostial negative remodelling as the first manifestation of Takayasu arteritis: a case report.2021BMC cardiovascular disorders
Chinese-language papers (not in the count)1
  1. [Clinical features and CT findings of Takayasu's arteritis associated pulmonary hypertension].2021Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases
Earlier papers (2016–2020)3
  1. Performance of the PET vascular activity score (PETVAS) for qualitative and quantitative assessment of inflammatory activity in Takayasu's arteritis patients.2020European journal of nuclear medicine and molecular imaging
  2. Contrast-enhanced Ultrasonography for Monitoring Arterial Inflammation in Takayasu Arteritis.2019The Journal of rheumatology
  3. [Association between platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio with disease activity in Takayasu arteritis patients].2018Zhonghua xin xue guan bing za zhi
All its trials on ClinicalTrials.gov, any status1
  1. Comparison of Mycophenolate Mofetil and Cyclophosphamide for Active Takayasu's ArteritisCompletedNCT03096275Study sitePhase 3Start 2017-03

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 1 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.1%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

10 hospitals in Xi'an for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led no English-language PubMed papers on Duchenne muscular dystrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

3 hospitals in Xi'an for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

3 hospitals in Xi'an for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led 10 of the 736 English-language PubMed papers on IgA nephropathy with an author in mainland China, 2021–2025: 1.4%.

Papers led
10
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 1120232024: 2220242025: 002025

7 hospitals in Xi'an for IgA nephropathy300 hospitals in China for IgA nephropathy

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgAN
    Phase
    Phase 3
    Started
    2026-04
    Registry
    NCT07390123

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 9 listed hospitals as study sitesBeijing, Changchun, Changsha, Huangshan City, Linyi, Shanghai, Wuhu, Xi'an, Zhanjiang

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersNephrology
Papers it led10
  1. Exploring the crosstalk molecular mechanisms between IgA nephropathy and Sjögren's syndrome based on comprehensive bioinformatics and immunohistochemical analyses.2024Clinical and experimental medicine
  2. Immune checkpoint activity exacerbate renal interstitial fibrosis progression by enhancing PD-L1 expression in renal tubular epithelial cells.2024Translational research : the journal of laboratory and clinical medicine
  3. Serum Long Noncoding RNA H19 and CKD Progression in IgA Nephropathy.2023Journal of nephrology
  4. Long-term outcomes of IgA nephropathy patients with less than 25% crescents and mild proteinuria.2022Clinical and experimental nephrology
  5. The clinicopathological characteristics and outcomes of IgA nephropathy with predominant lambda or kappa light-chain deposition.2022International urology and nephrology
  6. Expansion of Escherichia-Shigella in Gut Is Associated with the Onset and Response to Immunosuppressive Therapy of IgA Nephropathy.2022Journal of the American Society of Nephrology : JASNRCT
  7. Low-Dose Corticosteroid Combined With Mycophenolate Mofetil for IgA Nephropathy With Stage 3 or 4 CKD: A Retrospective Cohort Study.2021Clinical therapeutics
  8. The prognostic effect of immunosuppressive therapy in IgA nephropathy with stage 3 or 4 chronic kidney disease.2021Renal failure
  9. Alleviation of refractory IgA nephropathy by intensive fecal microbiota transplantation: the first case reports.2021Renal failure
  10. Hematuria was a high risk for renal progression and ESRD in immunoglobulin a nephropathy: a systematic review and meta-analysis.2021Renal failure
Chinese-language papers (not in the count)1
  1. [Retrospective Analysis of the Effect of Uric Acid on the Prognosis of Immunoglobulin A Nephropathy With Stage 3-4 Chronic Kidney Disease].2023Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition
Earlier papers (2016–2020)5
  1. A Comparative Study of the Gut Microbiota Associated With Immunoglobulin a Nephropathy and Membranous Nephropathy.2020Frontiers in cellular and infection microbiology
  2. Renal survival and risk factors in IgA nephropathy with crescents.2020International urology and nephrology
  3. Comparison of the effects of valsartan plus activated vitamin D versus valsartan alone in IgA nephropathy with moderate proteinuria.2020International urology and nephrologyRCT
  4. Treatment for IgA nephropathy with stage 3 or 4 chronic kidney disease: low-dose corticosteroids combined with oral cyclophosphamide.2020Journal of nephrology
  5. The landscape and diagnostic potential of T and B cell repertoire in Immunoglobulin A Nephropathy.2019Journal of autoimmunity
All its trials on ClinicalTrials.gov, any status3
  1. Efficacy and Safety of CD19 CAR-γδ T Cells in the Treatment of Relapsed/Refractory Autoimmune NephropathyNot yet recruitingNCT07535138Lead (inferred)Early phase 1Start 2026-05
  2. Fecal Microbiota Transplantation for Refractory IgA NephropathyStatus unknownNCT03633864Lead (inferred)Phase 2Start 2017-11
  3. Phase Ⅲ Study of Efficacy and Safety of HSK39297 Tablet in Treatment of Patients With Primary IgANRecruitingNCT07390123Study sitePhase 3Start 2026-04

Run the PubMed searchClinicalTrials.gov

Other diseases

Gaucher disease

戈谢病

Led no English-language PubMed papers on Gaucher disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

1 hospital in Xi'an for Gaucher disease40 hospitals in China for Gaucher disease

No open trial on Gaucher disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicine
Chinese-language papers (not in the count)1
  1. [Clinicopathological study of Gaucher disease].2022Zhonghua bing li xue za zhi = Chinese journal of pathology

Run the PubMed searchClinicalTrials.gov

Other diseases

Niemann–Pick disease type C

尼曼-匹克病 C 型

Led 1 of the 16 English-language PubMed papers on Niemann–Pick disease type C with an author in mainland China, 2021–2025: 6.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

1 hospital in Xi'an for Niemann–Pick disease type C15 hospitals in China for Niemann–Pick disease type C

No open trial on Niemann–Pick disease type C lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersNeurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led 17 of the 300 English-language PubMed papers on primary biliary cholangitis with an author in mainland China, 2021–2025: 5.7%.

Papers led
17
2021–2025
Trials led
13
any status, ClinicalTrials.gov
Open trials led
6
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 1120212022: 2220222023: 5520232024: 5520242025: 442025

4 hospitals in Xi'an for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

Open trials with this hospital 7

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 13 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC Therapy
    Phase
    Phase 3
    Started
    2025-12
    Registry
    NCT07296458

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 1 listed hospital as study siteGuangzhou, Xi'an

  2. Recruiting
    Fenofibrate in Primary Biliary Cholangitis: a Real World Study
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06755151

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  3. Recruiting
    Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World Study
    Phase
    Phase 3
    Started
    2024-01
    Registry
    NCT06755541

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  4. Recruiting
    Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary Cholangitis
    Phase
    Phase 2/Phase 3
    Started
    2023-02
    Registry
    NCT05749822

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 11 listed hospitals as study sitesBeijing, Changsha, Chengdu, Guangzhou, Kunming, Nanjing, Shenyang, Tianjin, Xi'an, Yan'an, Zhengzhou

  5. Recruiting
    Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary Cholangitis
    Phase
    Phase 3
    Started
    2023-02
    Registry
    NCT05751967

    Age 18 years to 75 years (registered criteria)

    Led by Xijing Hospital; 6 listed hospitals as study sitesChengdu, Guangzhou, Lanzhou, Nanjing, Shenyang, Tianjin, Xi'an

  6. Recruiting
    Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)
    Phase
    Phase 2/Phase 3
    Started
    2017-04
    Registry
    NCT06365424

    Age 18 years to 75 years (registered criteria)

    Led by Xijing HospitalXi'an

  7. Recruiting
    Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis
    Phase
    Phase 3
    Started
    2023-09
    Registry
    NCT06051617

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 17 listed hospitals as study sitesBeijing, Changchun, Chengdu, Chongqing, Fuzhou, Guangzhou, Guiyang, Hangzhou, Hefei, Shanghai, Urumqi, Wuhan, Xi'an, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersGastroenterology / hepatologyRheumatology & immunologyPediatricsPathology / laboratory medicine
Papers it led17
  1. The Treatment of Primary Biliary Cholangitis: Time for Personalized Medicine.2025Clinical reviews in allergy & immunology
  2. The prognostic value of anti-gp210 and anti-centromere antibodies in patients with primary biliary cholangitis: Enhancing the prognostic utility on the GLOBE scoring system.2025Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  3. Risk stratification for patients with primary biliary cholangitis: early versus advanced-stage or non-cirrhosis versus cirrhosis?2025Hepatology international
  4. Low-risk individuals with primary biliary cholangitis and significant liver stiffness: prognosis and treatment.2025Hepatology international
  5. Hypercholesterolemia Is Associated With Dysregulation of Lipid Metabolism and Poor Prognosis in Primary Biliary Cholangitis.2024Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  6. Prognostic significance of liver stiffness in patients with primary biliary cholangitis: validation of Baveno VII criteria.2024Hepatology international
  7. Differences in the perceptions of patients with primary biliary cholangitis and physicians from various hospital departments: An online survey.2024Journal of digestive diseases
  8. Innate lymphoid cell subsets in the pathogenesis of primary biliary cholangitis.2024Journal of gastroenterology and hepatology
  9. Dissecting causal relationships between primary biliary cholangitis and extrahepatic autoimmune diseases based on Mendelian randomization.2024Scientific reports
  10. Integrative bioinformatics analysis and experimental validation of key biomarkers for risk stratification in primary biliary cholangitis.2023Arthritis research & therapy
  11. Laboratory risk factors for coexistent primary biliary cholangitis in patients with Sjögren's syndrome: a retrospective study.2023BMC gastroenterology
  12. Fenofibrate normalizes alkaline phosphatase and improves long-term outcomes in patients with advanced primary biliary cholangitis refractory to ursodeoxycholic acid.2023Gastroenterologia y hepatologia
  13. Prediction and evaluation of high-risk patients with primary biliary cholangitis receiving ursodeoxycholic acid therapy: an early criterion.2023Hepatology internationalRCT
  14. Effectiveness of Fenofibrate in Treatment-Naive Patients With Primary Biliary Cholangitis: A Randomized Clinical Trial.2023The American journal of gastroenterologyRCT
  15. Efficacy and safety of fenofibrate addition therapy in patients with cirrhotic primary biliary cholangitis with incomplete response to ursodeoxycholic acid.2022Hepatology communications
  16. Primary biliary cholangitis: personalized medicine for optimal therapeutic opportunities.2022Science bulletin
  17. Decreased infiltration of CD4+ Th1 cells indicates a good response to ursodeoxycholic acid (UDCA) in primary biliary cholangitis.2021Pathology, research and practice
Chinese-language papers (not in the count)4
  1. [Progress in diagnosis and treatment of primary biliary cholangitis].2025Zhonghua nei ke za zhi
  2. [Progresses and hot spots of primary biliary cholangitis in the past decade].2024Zhonghua nei ke za zhi
  3. [Primary biliary cholangitis in a child].2022Zhonghua er ke za zhi = Chinese journal of pediatrics
  4. [Research progress of osteoporosis in primary biliary cholangitis].2022Zhonghua nei ke za zhi
Earlier papers (2016–2020)6
  1. A nomogram based on pretreatment clinical parameters for the prediction of inadequate biochemical response in primary biliary cholangitis.2020Journal of clinical laboratory analysis
  2. [Research progress on risk factors for poor response of ursodeoxycholic acid in primary biliary cholangitis].2019Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  3. [Study the role of lysosome-associated membrane protein type 2A for immune-mediated liver injury of primary biliary cholangitis].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  4. [Screening of familial primary biliary cholangitis and research on low-frequency mutations by whole-exome sequencing].2018Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  5. [Primary biliary cholangitis and bile acid metabolism].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
  6. [An interpretation of 2017 EASL clinical practice guidelines: the diagnosis and management of patients with primary biliary cholangitis].2017Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
All its trials on ClinicalTrials.gov, any status17
  1. FIREFLY Trial: Fenofibrate Intervention---Randomized Evaluation in First-Line PBC TherapyRecruitingNCT07296458Lead sponsorPhase 3Start 2025-12
  2. Fenofibrate in Primary Biliary Cholangitis: a Real World StudyRecruitingNCT06755151Lead sponsorPhase 3Start 2024-01
  3. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary Cholangitis: a Real World StudyRecruitingNCT06755541Lead sponsorPhase 3Start 2024-01
  4. Fenofibrate for Compensated Cirrhosis Patients With Primary Biliary CholangitisRecruitingNCT05749822Lead sponsorPhase 2/Phase 3Start 2023-02
  5. Fenofibrate Combined With Ursodeoxycholic Acid in Subjects With Primary Biliary CholangitisRecruitingNCT05751967Lead sponsorPhase 3Start 2023-02
  6. Fenofibrate in Patients With Primary Biliary Cholangitis (PBC)RecruitingNCT06365424Lead sponsorPhase 2/Phase 3Start 2017-04
  7. Fenofibrate in Subjects With Primary Biliary Cholangitis (PBC)Active, not recruitingNCT07104201Lead sponsorEarly phase 1Start 2025-03
  8. Mesenchymal Stem Cell Transplantation for Refractory Primary Biliary CholangitisStatus unknownNCT03668145Lead sponsorN/AStart 2017-11
  9. Fuzhenghuayu in Combination With Ursodeoxycholic Acid in Primary Biliary CirrhosisStatus unknownNCT02916290Lead sponsorPhase 3Start 2016-01
  10. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CirrhosisCompletedNCT02823353Lead sponsorPhase 3Start 2016-04
  11. Fenofibrate for Patients With Primary Biliary Cirrhosis Who Had An Inadequate Response to Ursodeoxycholic AcidRecruitingNCT02823366Lead sponsorPhase 3Start 2016-01
  12. Fuzhenghuayu for Patients With PBC Who Had An Inadequate Response to Ursodeoxycholic AcidStatus unknownNCT02916641Lead sponsorPhase 3Start 2016-01
  13. A Pilot Study of Fenofibrate and Ursodeoxycholic Acid in the Treatment of Newly Diagnosed Primary Biliary CholangitisCompletedNCT06591455Lead (inferred)Early phase 1Start 2024-09
  14. Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated CirrhosisRecruitingNCT06051617Study sitePhase 3Start 2023-09
  15. A Multicenter, Randomized, Controlled Trial of Prednisone Combined With Ursodeoxycholic Acid in the Treatment of Primary Biliary Cholangitis With Moderate to Severe Interface Hepatitis CharacteristicsEnrolling by invitationNCT06591468Study sitePhase 2/Phase 3Start 2024-10
  16. Fenofibrate in Combination With Ursodeoxycholic Acid in Primary Biliary CholangitisActive, not recruitingNCT06174402Study sitePhase 2/Phase 3Start 2023-08
  17. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary sclerosing cholangitis

原发性硬化性胆管炎

Led 1 of the 100 English-language PubMed papers on primary sclerosing cholangitis with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

4 hospitals in Xi'an for primary sclerosing cholangitis89 hospitals in China for primary sclerosing cholangitis

No open trial on primary sclerosing cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersGastroenterology / hepatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Familial adenomatous polyposis

家族性腺瘤性息肉病

Led no English-language PubMed papers on familial adenomatous polyposis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

2 hospitals in Xi'an for familial adenomatous polyposis74 hospitals in China for familial adenomatous polyposis

No open trial on familial adenomatous polyposis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Primary Chemoprevention of Familial Adenomatous Polyposis With Berberine HydrochlorideCompletedNCT03333265Lead sponsorPhase 2/Phase 3Start 2017-09

Run the PubMed searchClinicalTrials.gov

Other linked evidence

Getting in touch

Name card to show staff or a driver

空军军医大学西京医院

Xijing Hospital

西安

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Xijing Hospital of Digestive Diseases; Xijing Hospital of Digestive Disease; XiJing Hospital; Xijing Hospital of The Fourth Military Medical University; Xijing Hospital Fourth Military Medical University; Xijing Hospital Affiliated to Fourth Military Medical University; Air Force Medical University Xijing Hospital; Xijing Hospital of Air Force Medical University

Suggest a correctionDownload the data